Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Thalassemias: Overview of Pathophysiology and Treatment

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

K. Fertrin

Impact and Risks of Chronic Anemia in Thalassemia Patients

Farrukh Shah

Case-Based Discussion: Managing Non-Transfusion-Dependent Thalassemia

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Taher

Managing Benign Hematology Disorders

Indy Hematology Review

C. Kessler

Thalassemia: Overview of Pathophysiology and Risk for Malignancies

Ali Taher

Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…

UChicago Medicine

A. Cooper

Managing the Benign Hematology Consult: Treatment Recommendations fo…

Indy Hematology Review

C. Kessler

Mitapivat for Thalassemia: Results From the Ph3 ENERGIZE-T Study

Stefan Eber

Highlights in Red Cell and Platelet Disorders From ASH 2023

Insights from 2023 ASH Annual Meeting

M. Blinder

ACP 2024 Insights: Sickle Cell Anemia - Diagnosis and Management of …

Insights from 2024 ACP Annual Meeting

M. Okam Achebe

Role of Antiplatelet and Anticoagulant Therapy: Managing Vaso-Occlus…

Erica Sparkenbaugh

Beyond Transfusion: Current Treatment Options for Managing Thalassem…

Abdulrahman Nasiri

Recent Gene Therapy Approvals in SCD: Clinical and Logistical Consid…

Nirmish Shah

Gene Therapy for Sickle Cell Disease: Are We Where They Wanted Us to…

Cayenne Wellness 15th Annual Hybrid Sickle Cell Disease Educational Summit

A. Sharma

Sickle Cell Disease 101

Cayenne Wellness 15th Annual Hybrid Sickle Cell Disease Educational Summit

I. Osunkwo

Hematologic Emergencies

Michigan Medicine

A. Ahmed

Outcomes of Lovo-Cel Gene Therapy in Sickle Cell Disease: 60-Month F…

Yale Cancer Center

J. Ryu

Updates in Therapeutics for Sickle Cell Disease

University of Colorado Division of Hematology

G. George

ASH 2023 Insights: "Pyruvate Kinase Activators - Targeting Red Cell …

Insights from 2023 ASH Annual Meeting

K. Kuo